KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis.

Helena Marzo-Ortega, Iain B McInnes, Mohamed Sharaf, Alen Zabotti, Emmanouil Rampakakis, Dennis McGonagle, Ahmed Abogamal, Pascal Richette, Georg Schett

Rheumatology (Oxford) 65(1) keaf490

PMID40971670
PMCIDPMC12862382
DOI10.1093/rheumatology/keaf490
发表日期2025-09-19
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

OBJECTIVE: To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR). METHODS: In the Phase IIIb COSMOS trial, 285 adults with TNFi-IR PsA were randomized (2:1) to receive guselkumab 100 mg or placebo at Week (W)0, W4, then every 8 weeks until W44. The Dactylitis Severity Score (DSS) and Leeds Enthesitis Index (LEI) assessed dactylitis and enthesitis, respectively. This post hoc analysis evaluated associations between W24 DR or ER and W48 achievement of stringent disease control measures using logistic regression. RESULTS: At baseline, 103/285 (36.1%) patients had dactylitis (DSS ≥ 1) and 190/285 (66.7%) had enthesitis (LEI ≥ 1). Patients with dactylitis were more likely to have enthesitis, more joint (SJC/DAPSA) and skin involvement, higher PGA score and lower BMI vs those without dactylitis. Patients with enthesitis were more likely to be female, and have dactylitis, more joints affected (SJC/TJC/DAPSA) and worse physical functioning (HAQ-DI/SF-36 PCS) vs those without enthesitis. Greater proportions of guselkumab- vs placebo-treated patients achieved DR/ER (W24: 44.8%/39.7% vs 25.0%/18.8%); rates increased through W48 among guselkumab-randomized patients (67.2%/55.6%). W24 resolution was associated with W48 achievement of stringent measures, including ACR50/70, DAPSA LDA/remission, PASI100, PASDAS LDA/VLDA and MDA/VLDA (odds ratios: DR, 3.28-13.38; ER, 2.88-6.09). CONCLUSION: Guselkumab treatment resulted in high DR/ER rates through W48 in TNFi-IR PsA patients. W24 DR/ER was associated with W48 disease control, providing valuable insights for clinical decision-making based on W24 treatment responses.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 3

Figure 3. Proportions of patients with enthesitis resolution over time, and remaining free from enthesitis at W24 and W48. Panel ( A ) shows the proportion of patients with enthesitis resolution over time, among those with LEI ≥ 1 at baseline. Panel ( B ) shows the proportion of patients remaining free from enthesitis at W24 and W48, among those with LEI = 0 at baseline. NRI/composite analysis used through W24; NRI analysis only beyond W24. LEI, Leeds Enthesitis Index; NRI, non-responder imputation; Q8W, every 8 weeks; W, Week

A

enthesitis resolution over time

Figure 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Proportion of patients with dactylitis resolution over time, and remaining free from dactylitis at W24 and W48. Panel ( A ) shows the proportion of patients with dactylitis resolution over time, among those with DSS ≥ 1 at baseline. Panel ( B ) shows the proportion of patients remaining free from dactylitis at W24 and W48, among those with DSS = 0 at baseline. NRI/composite analysis used through W24; NRI analysis only beyond W24. DSS, Dactylitis Severity Score; NRI, non-responder imputation; Q8W, every 8 weeks; W, Week
非 KM Figure
Figure 2Figure 2. Associations between dactylitis resolution at W24 and achievement of stringent measures of disease control at W48. Patients analysed were those randomized to guselkumab with DSS ≥ 1 at baseline. ACR, American College of Rheumatology; CI, confidence interval; DAPSA, Disease Activity in Psoriatic Arthritis; DSS, Dactylitis Severity Score; LDA, low disease activity; MDA, minimal disease activity; OR, odds ratio; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; VLDA, very low disease activity; W, Week
非 KM Figure
Figure 4Figure 4. Associations between enthesitis resolution at W24 and achievement of stringent measures of disease control at W48. Patients analysed were those randomized to guselkumab with LEI ≥ 1 at baseline. ACR, American College of Rheumatology; CI, confidence interval; DAPSA, Disease Activity in Psoriatic Arthritis; LDA, low disease activity; LEI, Leeds Enthesitis Index; MDA, minimal disease activity; OR, odds ratio; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; VLDA, very low disease activity; W, Week
非 KM Figure